OXiGENE to Present at BIO CEO and Investor Conference on February 12, 2008

OXiGENE to Present at BIO CEO and Investor Conference on February 12, 2008

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 5, 2008--Regulatory News:

    OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a clinical stage,
biopharmaceutical company developing novel therapeutics to treat
cancer and eye diseases, announced today that President and CEO
Richard Chin, M.D., will present a corporate overview and update at
the BIO CEO and Investor Conference on Tuesday, February 12, at 10:15
a.m. EST (7:15 a.m. PST), in the Waldorf-Astoria hotel's Norse Suite
in New York City, NY.

    A live and archived webcast of the presentation can be accessed
for 30 days following the presentation under the Investor Center tab
at www.oxigene.com.

    About OXiGENE, Inc.

    OXiGENE is a clinical-stage biotechnology company developing novel
small-molecule therapeutics to treat cancer and eye diseases. The
Company's major focus is the clinical advancement of drug candidates
that selectively disrupt abnormal blood vessels associated with solid
tumor progression and visual impairment. OXiGENE is dedicated to
leveraging its intellectual property position and therapeutic
development expertise to bring life saving and enhancing medicines to
patients.

OXiGENE, Inc.
Michelle Edwards, 415-315-9413
Investor Relations
medwards@oxigene.com